PREMMplus Permanent link to this article: ICARE Social Media Post April 2025 Colonoscopy Age in Lynch Syndrome: MSH6 and PMS2 carriers ICARE Social Media Post April 2025 Colonoscopy Age in Lynch Syndrome: MSH6 and PMS2 carriers A new study evaluating colonoscopy age in Lynch Syndrome patients with MSH6 and PMS2 mutations found that among MSH6 and PMS2 carriers, cancer was commonly found, even in those under age 30
Clinical studies show that participants experienced a mean weight loss of 15% over 68 weeks: In 4 weeks, participants experienced an average of 2% weight loss In 8 weeks, they experienced 4% weight loss The good news is that most of the people in the study lost weight on Wegovy: Over 86% of participants lost at least 5% of their body weight About 70% lost 10% of their body weight or more Note: The FDA has not approved Ozempic and Rybelsus for weight loss
Key evaluation domains included: Program reach (partners served, demographics and counties) Financial investment (technology and total funding) Improved access to care and support services Program sustainability post-grant Impact on clients and grantee organizations Uniqueness of Wellstars investment Social return on investment Key evaluation findings and impact Health equity and social determinants of health The evaluation highlighted the alignment of the CTP with Wellstars commitment to addressing social determinants of health, or factors that can affect a persons well-being, including access to food, housing and transportation
What are the most common side effects of taking both medications
Studies have shown that it leads to significant weight loss by enhancing metabolism and targeting fat stores
